Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy

April 02, 2024 By The ASCO Post Staff

Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses phase III findings from the KEYNOTE-756 trial, which shows that adding pembrolizumab to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates in patients with early-stage, high-risk, estrogen receptor–positive or HER2-negative breast cancer. (ER+/HER2−). The regimen shifted more patients to lower residual cancer burden categories (Abstract 2).

Related Content